Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that the New Drug Application (NDA) for a new indication of furmonertinib mesylate tablets has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) – the proposed indication being adjuvant treatment of adult patients with non‑small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations following tumor resection.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE, NMPA (China) |
| Action | NDA accepted for a new indication |
| Product | Furmonertinib mesylate tablets |
| Proposed Indication | Adjuvant treatment of adult NSCLC patients with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations following tumor resection |
| Announcement Date | 21 Sep 2026 |
| Drug Classification | Class 1 innovative drug in China, fully independent intellectual property |
| Next Steps | CDE technical review; approval decision timeline – not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Furmonertinib, a third‑generation EGFR tyrosine kinase inhibitor (EGFR‑TKI) independently developed by Allist Pharmaceuticals with fully independent intellectual property rights and designated a Class 1 innovative drug in China.
- Mechanism: Third‑generation EGFR‑TKIs selectively inhibit EGFR sensitizing mutations – including exon 19 deletion and exon 21 (L858R) substitution – while sparing wild‑type EGFR, improving efficacy‑to‑tolerability balance over earlier generations.
- Adjuvant Rationale: In resected EGFR‑mutant NSCLC, adjuvant TKI therapy aims to eliminate residual micrometastatic disease and reduce recurrence risk – the setting targeted by the newly accepted NDA.
Approval History & Reimbursement Status
| Timing | Indication Approved | Line / Setting | Reimbursement |
|---|---|---|---|
| March 2021 | Locally advanced or metastatic NSCLC progressed during/after EGFR‑TKI treatment, with confirmed EGFR T790M mutation‑positive disease | Second‑line | Included in national medical insurance reimbursement list |
| June 2022 | Locally advanced or metastatic NSCLC harboring EGFR exon 19 deletion or exon 21 (L858R) substitution mutations | First‑line | Included in national medical insurance reimbursement list |
| February 2026 | EGFR exon 20 insertion mutation‑positive NSCLC | Second‑line | Not disclosed |
| Pending (NDA accepted 21 Sep 2026) | Adjuvant treatment of resected NSCLC with EGFR exon 19 deletion or exon 21 (L858R) | Adjuvant | – |
Market Impact & Outlook
- Label Expansion Strategy: The adjuvant NDA would extend furmonertinib from the advanced/metastatic setting into early‑stage post‑surgical care, opening a substantially larger patient population and a longer treatment duration per patient.
- Reimbursement Foundation: With both the first‑line and second‑line indications already included in the national medical insurance reimbursement list, furmonertinib has established market access that would support rapid uptake of an approved adjuvant indication.
- Mutation Coverage Breadth: The accumulated label – T790M second‑line (2021), classical‑mutation first‑line (2022), exon 20 insertion second‑line (Feb 2026) – gives furmonertinib one of the broadest EGFR mutation coverage profiles among China‑developed third‑generation TKIs.
- Competitive Dynamics: The adjuvant EGFR‑TKI field in China is intensifying as peers pursue the same post‑resection opportunity; CDE review outcome and any subsequent national reimbursement inclusion will be decisive for Allist’s positioning.
- Key Catalysts: CDE technical review progress and the approval decision for the adjuvant indication; trial identifiers and enrollment data supporting the NDA – not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding CDE review timelines, regulatory approval of the adjuvant indication, reimbursement outcomes, and commercial performance of furmonertinib. Actual results may differ materially due to risks including review determinations, clinical evidence requirements, competitive dynamics, and market adoption.-Fineline Info & Tech
